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Breast milk is the perfect nutrition for infants, a result of millions of years of evolution. In 
addition to providing a source of nutrition, breast milk contains a diverse array of microbiota 
and myriad biologically active components that are thought to guide the infant’s develop-
ing mucosal immune system. It is believed that bacteria from the mother’s intestine may 
translocate to breast milk and dynamically transfer to the infant. Such interplay between 
mother and her infant is a key to establishing a healthy infant intestinal microbiome. 
These intestinal bacteria protect against many respiratory and diarrheal illnesses, but are 
subject to environmental stresses such as antibiotic use. Orchestrating the development 
of the microbiota are the human milk oligosaccharides (HMOs), the synthesis of which 
are partially determined by the maternal genotype. HMOs are thought to play a role 
in preventing pathogenic bacterial adhesion though multiple mechanisms, while also 
providing nutrition for the microbiome. Extracellular vesicles (EVs), including exosomes, 
carry a diverse cargo, including mRNA, miRNA, and cytosolic and membrane-bound 
proteins, and are readily detectable in human breast milk. Strongly implicated in cell–cell 
signaling, EVs could therefore may play a further role in the development of the infant 
microbiome. This review considers the emerging role of breast milk microbiota, bioactive 
HMOs, and EVs in the establishment of the neonatal microbiome and the consequent 
potential for modulation of neonatal immune system development.
Keywords: breast milk, microbiota, microbiome, human milk oligosaccharides, exosomes, extracellular vesicles, 
infant microbiome, breast milk microbiome
iNTRODUCTiON
Breastfeeding confers protection against respiratory and gastrointestinal infections and is associated 
with a reduced risk of inflammatory diseases such as asthma, atopy, diabetes, obesity, and inflam-
matory bowel disease (1–7). Prolonged and exclusively breastfed infants have improved cognitive 
development (8, 9). Human milk continues the transfer of immunity from mother to child that 
started in utero, providing a nurturing environment that protects against infection and develops the 
infant intestinal mucosa, microbiota, and their own immunologic defenses. Breast milk is a special-
ized secretion in which immune response is highly targeted against microorganisms in the mother’s 
gut and airway, providing an important defense against the same pathogens likely encountered by 
her infant (10). More recent studies suggest that breast milk not only provides passive protection 
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but also directly modulates the immunological development of 
the breastfed infant through a variety of personalized microbial 
and immune factors transmitted from mother to child (11–14). 
These early imprinting events are crucial for immunologic and 
metabolic homeostasis.
Breast milk immune factors are at their highest concentrations 
in the colostrum (15), suggesting an immunologic function of 
milk when the infant is at highest risk of exposure to new patho-
gens. However, they continue to be dynamically present through-
out the lactation period. Bioactive factors transferred to the 
infant via breastfeeding including immunoglobulins, cytokines, 
chemokines, growth factors, hormones, and lactoferrin have been 
reviewed in detail elsewhere (15–17). This review will focus on the 
roles of breast milk microbiota in the establishment of the infant 
intestinal microbiota, human milk oligosaccharides (HMOs) in 
shaping the microbiota, and extracellular vesicles (EVs) in modu-
lation of the host–microbe interactions. Breast milk microbiota, 
HMOs, and EVs are emerging as areas of potential therapeutic 
interests due to their implications for infant immune develop-
ment, health, and scope for therapeutic manipulation.
BReAST MiLK MiCROBiOTA
Breast milk comprises several hundred bacterial species and 
harbors bacteria at concentrations of approximately 1,000 
colony-forming units (CFUs)/mL (18, 19). It is estimated 
that breastfed infants ingest up to 800,000 bacteria daily (20). 
Following a dose of microbes at birth (21), breast milk is the 
immediate next fundamental source of microbes seeding 
the infant’s gut (22, 23). Many epidemiologic studies have 
documented differences in the composition of gut microbiota in 
breastfed and formula-fed infants (24–26). Human milk directly 
contributes to the establishment of the infant intestinal micro-
biome (19, 20, 23, 27–29). Multiple studies have documented 
the sharing of specific microbial strains of Bifidobacterium, 
Lactobacillus, Enterococcus, and Staphylococcus species between 
breast milk and infant stool (30–32). During the first month of 
life, infants who primarily breastfeed share 28% of their stool 
microbes with their mother’s milk microbes. The frequency of 
shared microbes increases with the proportion of daily breast 
milk intake in a dose-dependent manner (23). These findings 
strongly suggest the transfer of microbes from breast milk to the 
infant gut. Although an interindividual variation in the types 
and abundance of different bacteria in human milk exists, the 
bacteria found in the infant gut most resemble the bacteria from 
their own mother (23).
While early studies employed culture-dependent methods, 
recent development of culture-independent techniques, such as 
next-generation sequencing, has expanded our understanding 
of the composition and diversity of the breast milk microbiome 
(33–35). Streptococcus and Staphylococcus species are the most 
commonly identified bacterial families in human milk, followed 
by Bifidobacterium, Lactobacillus, Propionibacteria, Enterococcus, 
and members of the Enterobacteriaceae family (23, 28, 35, 36). 
Several hundred bacterial species have been identified with 
higher diversity in colostrum compared to transition and mature 
milk (18).
The origin of bacteria in breast milk is not well established. 
Breast tissue itself contains a diverse population of bacteria (37). 
A dynamic cycling of bacteria between mother and infant with 
retrograde flow from maternal commensal skin flora to infant 
mouth flora during breastfeeding (38) likely contributes to the 
bacterial communities (39). However, commensal contamination 
does not fully account for the diversity of human milk microbes 
or the presence of strictly anaerobic species such as Bifidobacterium, 
Clostridium, or Bacteroides species. Milk microbial community 
composition has been shown to differ from communities on the 
surrounding areolar skin and infant mouth (35, 40). Another 
proposed theory is an enteromammary pathway whereby mater-
nal intestinal bacteria migrate to the mammary glands via an 
endogenous cellular route during pregnancy and lactation (19, 
28, 41). It has been hypothesized that bacteria first translocate 
the maternal gut by internalization in dendritic cells and then 
circulate to the mammary gland via the lymphatic and blood 
circulation (42). This specialized form of mother–infant com-
munication of transferring microbes from the mother’s gut to the 
infant via breastfeeding needs further investigation.
Maternal factors affect milk microbiota composition and 
diversity (Figure 1). Higher diversity has been reported in milk 
from mothers who deliver vaginally compared with C-section by 
some groups (18, 43, 44) but not others (23, 45). Milk bacterial 
profiles do not significantly differ in relation to maternal age, infant 
gender, or race/ethnicity within a geographical region but do dif-
fer across geographic locations of Europe, Africa, and Asia (23, 
45, 46). Bifidobacterium species concentration was higher in term 
deliveries than preterm deliveries (44). Total bacteria concentra-
tion using quantitative PCR is lower in colostrum than in transi-
tional and mature milk, with increasing levels of Bifidobacterium 
and Enterococcus species over time (18, 44). Maternal health 
alters milk microbiota composition and diversity as evidenced 
by comparative studies of healthy mothers to those with obesity, 
celiac disease, and human immunodeficiency virus (HIV) (18, 47, 
48). Immunomodulatory cytokines secreted in breast milk from 
healthy women such as transforming growth factor beta (TGFβ) 
1 and TGFβ2 are associated with increased early-life microbial 
richness, evenness, diversity, and increased abundance of taxa 
protective against atopic diseases (49). Unsurprisingly, maternal 
antibiotic use and chemotherapy decrease bacterial diversity in 
breast milk (50, 51); how this impacts on the infant microbiome 
and immune system development in the long term is currently 
unknown. More studies are warranted to understand how 
maternal genetics, culture, environment, nutritional status, and 
inflammatory states from acute or chronic diseases affect breast 
milk microbiota.
Role of Breast Milk Microbiota in the 
infant Gut
Breast milk bacteria have both immediate- and long-term roles 
in reducing the incidence and severity of bacterial infections in 
breastfed infants by multiple mechanisms. Commensal bacteria 
can competitively exclude or express antimicrobial properties 
against pathogenic bacteria. For example, Lactobacilli isolated 
from breast milk have been shown to inhibit adhesion and growth 
FiGURe 1 | Factors that influence maternal breast milk microbiome and proposed mechanism of how breast milk may alter the infant gut microbiome and health 
outcome. A myriad of environmental, genetic, and immune factors personalize a mother’s milk for delivery to her infant. Starting from the initial feeding, the breast 
milk microbes and human milk oligosaccharides contribute to the composition and diversity of the infant gut microbiome. The initial gut microbes may continue to 
promote colonization of a healthy community or an aberrant community. During the critical window of immune development, the community types may induce 
metabolic alterations leading to differing immune phenotypes and long-term health outcomes. SCFA, short-chain fatty acids.
3
Le Doare et al. Milk: Infant Microbiota and Immunity
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 361
of gastrointestinal pathogens, including Escherichia coli, Shigella 
spp, Pseudomonas spp, and Salmonella spp strains (52–54). Five 
breast milk Lactobacilli strains increased mucin gene expression 
by intestinal enterocytes to form an antibacterial barrier (53). 
Administration of a breast milk Lactobacilli strain in a double-
blind controlled trial to infants 6–12 months of age reduced the 
incidence of gastrointestinal, respiratory, and total infections by 
46, 27, and 30%, respectively (55). The significant increase in 
bacterial counts of Lactobacilli and bifidobacteria in the experi-
mental group compared with the controls was thought to explain 
the reduced clinical infection episodes although the pathogenic 
bacteria counts were not measured. Another study found that 
30% of human milk contains nisin-producing bacteria that can 
survive passage through the intestine (56). Nisin is a bacteriocin 
used by the dairy industry to prevent spore germination and 
inhibit Clostridium botulinum and Bacillus cereus. Staphylococcus 
epidermidis and Streptococcus salivarius from expressed breast 
milk also possesses antimicrobial activity against pathogenic 
Staphylococcus aureus (20). Although there are many studies 
of antimicrobial peptides and molecules in the intestine, more 
studies are necessary to understand the specific antimicrobial 
activities of breast milk bacteria.
Increasing evidence in animals points to the instrumental 
role of microbiota in the development and instruction of the 
immune system (57, 58). In the absence of intestinal bacteria, 
animals have defects in lymphoid tissue development within 
the spleen, thymus, and lymph nodes. Germ-free intestines have 
reduced numbers of lamina propria CD4+ cells, IgA-producing 
cells, and hypoplastic Peyer’s patches (59). Germ-free mice typi-
cally are Th2 skewed but achieve a balance of Th1/Th2 cytokine 
production after the introduction of symbiotic bacteria (60). 
Breast milk Lactobacillus strains have been shown to enhance 
macrophage production of Th1 cytokines including Il-2, IL-12, 
and TNF-alpha (61). An early human study has suggested better 
Th1 responses in breastfed children compared to formula-fed 
children with immunomodulating effects lasting beyond weaning 
(62). Another in vitro study showed that Lactobacillus fermentum 
and Lactobacillus salivarius were potent activators of natural 
killer cells affecting innate immunity as well as moderate activators 
of CD4+ and CD8+ T cells and regulator T cells affecting acquired 
immunity (63). Breastfed rhesus macaque infants develop distinct 
gut microbiota and robust populations of memory T  cells and 
T helper 17 cells compared to bottle-fed infants (64). Whether 
these mechanisms also exists in humans is not yet known.
Critical window of Opportunity for 
immune effects
The World Health Organization recommends exclusive breast-
feeding during the first 6 months of life (65). This time period of 
exclusive milk ingestion is also a critical window for microbial 
imprinting (23, 66, 67). The infant microbiome comprises a 
dynamic community of bacteria that transforms throughout 
infancy and into early childhood, but the community assembly is 
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non-random and depends on early-life events (57, 66). Dysbiosis 
during this critical developmental window during a time of 
exclusive milk ingestion may have long-term health implications 
(57, 68). Germ-free mice have an overaccumulation of invariant 
natural killer (iNKT) cells leading to susceptibility to colitis, 
but colonization with standard microbiota before 2  weeks of 
life but not after, normalizes iNKT cell numbers and protected 
against colitis (69). Similarly, germ-free adult mice have elevated 
serum IgE levels associated with exaggerated allergic responses, 
but mice colonized with standard microbiota before 4  weeks 
of age, but not after, have normal IgE levels (70). Oral admin-
istration of Bifidobacterium breve in mice induces proliferation 
of FoxP3+ regulatory T  cells, but only if administered during 
the pre-weaning stage (54). Even transient perturbations in the 
microbiota in early life with penicillin is sufficient to induce 
sustained metabolic alterations and changes in the expression of 
immune genes in mice (68). Longitudinal human cohorts have 
supported the long-term implications of early dysbiosis. Arrieta 
et  al. showed transient gut dysbiosis during the first 100  days 
of life put infants at higher risk for asthma (71). The relative 
abundance of Lachnospira, Veillonella, Faecalibacterium, and 
Rothia was significantly lower in children at risk of asthma. These 
genera are present in breast milk (23, 36). Fujimura et al. found 
a microbiota conformation that was significantly associated with 
a higher risk of atopy; the conformation was only detectable in 
children younger than 6 months. By using fecal water from these 
infants cultured ex vivo with human adult peripheral T  cells, 
the investigators showed enhanced induction of IL4+ CD4+ 
T  cells and decreased abundance of CD4+ CD25+ FOXP3+ 
cells, suggesting that dysbiosis promotes CD4+ T cell dysfunc-
tion associated with atopy (72). The progressive establishment 
of the infant microbiota is vital for educating their immune 
system to tolerance and reactivity to maintain health throughout 
life. A recent study by Bäckhed et al. suggests that cessation of 
breastfeeding rather than introduction of solid foods is the major 
driver in the development of an adult microbiota (73). Indeed, 
Ding and Schloss found that history of breastfeeding as an infant 
dictated bacterial community composition as adults (74).
Breast Milk virome
Viruses are also known to be transmitted through breast milk 
(75) and likely contribute to the gut ecology of the developing 
infant. The assembly of phage and eukaryotic components of the 
infant gut virome is affected by health and nutritional status (76). 
Breitbart et al. did not find similar viral sequences in maternal 
breast milk and the infant stool in their one infant followed 
over time (77). However, a recent study of 25 mother–infant 
pairs identified bifidobacterial communities and bifidophages 
in maternal milk and infant stool, strongly suggesting vertical 
transmission through breastfeeding (78). Because the majority 
of viruses inhabiting the infant and adult gut are bacteriophages 
(77, 79), they have the ability to kill bacteria or provide them 
with potentially beneficial gene functions to shape the bacte-
rial community and long-term health. Longitudinal studies 
to determine the role of breastfeeding in the establishment of 
the infant gut virome and the viral–bacterial interactions are 
warranted.
HUMAN MiLK OLiGOSACCHARiDeS
Human milk oligosaccharides (HMO) may further influence the 
establishment of a healthy microbiome, by binding potentially 
harmful bacteria in the intestinal lumen, asserting direct anti-
microbial effects, modulating the intestinal epithelial cell immune 
response, and thereby promoting the growth of “good bacteria” 
(Figure  2). HMOs are soluble complex carbohydrates that are 
synthesized in the mammary glands dependent on maternal 
genotype, including the genes that determine the Lewis blood 
group antigen.
HMO are indigestible by the infant. Instead, they function as 
prebiotics, encouraging the growth of certain strains of beneficial 
bacteria, such as Bifidobacterium infantis, within the infant gas-
trointestinal tract (80), thus preventing infection by allowing the 
microbiota to outcompete potential pathogenic organisms (81, 
82). Once ingested by the infant, HMOs are thought to inhibit 
the adherence of pathogens to the intestinal epithelium by acting 
as a decoy receptor for pathogens, which prevents attachment to 
host cells, thereby preventing pathogen adhesion and invasion 
(83). HMOs are also thought to have direct antimicrobial effects 
on certain pathogens (81). Finally, HMOs have been observed 
to modulate intestinal epithelial cell responses, as well as act as 
immune modulators. HMOs alter the environment of the intes-
tine, by reducing cell growth, and inducing differentiation and 
apoptosis (84). They alter immune responses by shifting T cell 
responses to a balanced Th1/Th2 cytokine production (85).
Genetic differences are responsible for differences in HMO 
profiles in breast milk (86–89), although HMO abundance 
changes throughout lactation. Therefore, mothers possessing 
different genotypes, and thus different HMO profiles, may pro-
tect their infants against certain infections to a greater or lesser 
extent, depending on the presence of specific HMOs. Likewise, 
the different HMOs produced alter the types of microbiota 
colonizing infants, as well as the timing of the establishment 
of the microbiota (90). Because of their complexity, no human 
milk identical HMOs have been synthesized. However, non-
human milk-derived alternatives that may have similar bioactive 
properties are gaining interest. In a recent placebo-controlled 
trial of 4,556 infants from India, a plant oligosaccharide, fructoo-
ligosaccharide, was given to infants together with Lactobacillus 
plantarum and demonstrated a reduced risk of sepsis and death 
in those in the treatment arm (RR, 0.6; CI, 0.48–0.74) compared 
to those in the control arm (91). The results highlight a potential 
role for HMOs and non-milk oligosaccharides in preventing 
neonatal infection.
HMO are thought to play an important role in preventing 
neonatal diarrheal and respiratory tract infections (92, 93). 
Several HMOs have been implicated in protection against bacte-
rial and viral infections in neonates, including fucosyltransferase 
enzyme (FUT3), associated with the Lewis–Secretor gene (89) 
and 2′-fucosyllactose (2′-FL), associated with the Secretor gene 
(FUT2) (87). High concentrations of 2′-FL are associated with 
reduced risk of infant Campylobacter jejuni (94) and rotavirus 
infections (95). However, it has been noted that there is a rota-
virus strain-specific effect of different HMOs, both alone and in 
combination (95, 96). Lewis–secretor positive infants in Burkina 
FiGURe 2 | Mechanism of action of HMO to prevent aberrant pathogen colonization. HMO may bind directly to bacteria in the gut lumen causing conformational 
change in bacterial binding sites and preventing binding to cell receptors; alternatively, HMO may bind directly to gut epithelial cells causing altered expression of cell 
receptors, which prevent pathogen binding to gut epithelial cells. HMO, human milk oligosaccharide.
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Faso and Nicaragua appear to have increased susceptibility to 
rotavirus infection compared to Lewis-negative infants. As the 
Lewis antigen is partially responsible for HMO abundance, this 
finding may explain the reduced efficacy of the live oral rotavirus 
vaccine in Africa where the majority of women are Lewis–Secretor 
negative (96). Conversely, an observational study undertaken in 
the United States found severe rotavirus gastroenteritis to be 
essentially absent in children who had a genetic polymorphism 
that inactivates FUT2 expression on the intestinal epithelium, 
which may indicate further strain-specific adaptations of HMOs 
(97). Infants who received milk containing a low concentration of 
lacto-N-difucohexaose have an increased incidence of calicivirus 
diarrhea (98). Other HMO combinations in breast milk have also 
been associated with reduced risk of HIV transmission in Zambia 
(99).
It has been suggested that HMOs could be used therapeuti-
cally to harness these antibiotic benefits together with standard 
antibiotics (100, 101). Research to date has primarily focused on 
developing such adjuncts by investigating antiadhesive properties 
of HMOs in vitro. These include the ability of HMOs to reduce 
Streptococcus pneumoniae adherence to cells of the oropharynx 
(102) and gastrointestinal adherence with Escherichia coli 
(103–105). Specific HMOs such as FUT3 have been implicated 
in increased killing of Group B Streptococcus (GBS) in  vitro 
(106–108). The Bode laboratories have determined that GBS 
requires specific HMO to proliferate in  vitro (101), Further 
in vitro investigation revealed that GBS uses a glycosyltransferase, 
which incorporates HMOs into the cell membrane, preventing 
bacterial proliferation. The Townsend and Le Doare laboratories 
have also identified Lewis–Secretor status to be important in 
reducing biofilm associated with GBS (106, 107). Further studies 
have identified that HMO-2′-FL also acts as a decoy receptor 
for norovirus (109). Animal models also report increased Th1 
responses against RSV in mice given a prebiotic containing 
HMOs (110). HMOs are emerging as a novel potential adjunct to 
antibiotic therapy, but there is much uncertainty as to individual 
HMO function and synthesizing individual HMOs in the labora-
tory for use in clinical trials has proven problematic.
exTRACeLLULAR veSiCLeS AND THeiR 
CARGO
One of the most recently identified breast milk components 
that may alter the intestinal immune response and subsequent 
establishment of the microbiota are the extracellular vesicles (EV) 
that contain a rich protein cargo, capable of influencing the local 
immune response to bacterial challenge (111, 112). Hence, the 
discovery 10 years ago that human breast milk contains abundant 
EVs has garnered a lot of attention in the field (113). EVs contain 
a diverse cargo, including mRNA, miRNA, and cytosolic and 
membrane proteins and have been demonstrated to be intricately 
involved in cell–cell signaling. EVs include exosomes, which form 
through the endosomal pathway, and are released from cells fol-
lowing fusion of multivesicular endosomes with the plasma mem-
brane. The larger (0.1–2 µM), more heterogenous microvesicles are 
formed through direct blebbing from the cell plasma membrane. 
It is important to note that many breast milk studies use the term 
“exosomes,” but do not separate exosomes from other vesicles, 
neither conceptually nor physically. Unless the isolation procedure 
takes advantage of exosomes’ known size or flotation density (e.g., 
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through sucrose gradients, or size exclusion chromatography) or 
their known markers (i.e., by immunomagnetic isolation, e.g., 
anti-tetraspanin beads), isolated vesicles cannot be definitively 
described as exosomes. Both ultracentrifugation and PEG-based 
reagents such as Exoquick™, commonly used in breast milk 
studies to date, will pellet other vesicles as well as non-vesicular 
proteins, including RNA-binding proteins. Studies that use these 
methods have still revealed exciting potential for breast milk EVs, 
in terms of biomarkers, or biological activity in vivo. The Nolte- 
‘t Hoen group have published a useful study that compares EV 
isolation methods from breast milk (114).
Breast milk EVs contain RNA (115), miRNA, and long 
non-coding RNA (116). Several studies that profiled miRNA in 
breast milk exosomes found enrichment in multiple biological 
functions, including regulation of actin cytoskeleton, glycolysis/
gluconeogenesis, aminoacyl-tRNA biosynthesis, pentose phos-
phate pathway, galactose metabolism, and fatty acid biosynthesis, 
as well as a wide range of immunological pathways (117–120). 
Likewise, proteomic analysis of human breast milk EVs revealed 
that the majority of proteins mapped to immune cell origin 
(121). Interestingly, a large number of these proteins had not 
been previously identified in human breast milk, demonstrating 
that exploration of EV cargoes may reveal novel biomarkers 
and functional pathways for further investigation. Exosomes in 
bovine milk are also enriched in proteins involved in immune 
response and growth (122).
Exosomes can mediate delivery of novel functional miRNA 
and mRNA to recipient cells (123). Whether miRNAs in breast 
milk exosomes are functional in the human digestive system is 
still relatively unknown; some studies show that exosomes pro-
tect miRNAs from digestion (118, 124), while others show that 
miRNAs are degraded by intestinal contents (125). Certainly, 
breast milk mRNAs and miRNAs can be taken up by cells and 
elicit functional effects in  vitro, suggesting the exciting pos-
sibility that they may be able to alter protein expression at the 
neonatal mucosal surface, impacting on the development of the 
infant’s immune system. These functional effects demonstrated 
thus far include inhibition of in vitro T cell cytokine production 
and boosting regulatory T cells (113) and inhibition of HIV-1 
infection of dendritic cells (126). Liao et al. also recently demon-
strated that milk-derived EVs enter human intestinal crypt-like 
cells, with some localization to the cell nucleus; thus, this is a 
potential mechanism for delivery of immunoregulatory genetic 
material from mother-to-infant cells (127). Administration of 
breast milk exosomes increases intestinal epithelial prolifera-
tion in both pigs (128) and rats (129), suggesting that they also 
have the potential to promote normal intestinal development 
and function in neonates. In addition to acting in the intestinal 
tract, EVs could potentially exert effects in the oropharynx and 
nasopharynx. Thus, breast milk EVs could alter the neonatal 
immune response to oral vaccines, respiratory pathogens and 
colonization.
Extracellular vesicles also have the potential to modulate the 
host–microbe interaction. Epithelial and immune cell responses 
to gut microbes Lactobacillus or Bifidobacterium are modulated 
in the presence of EVs from serum (111). These EV enhance 
aggregation and phagocytosis of bacteria, as well as modulating 
TLR responses. Whether these activities are also performed by 
breast milk EVs is not known. As well as human milk, EVs also 
have been detected in porcine (128), bovine (122), and murine 
(125) milk, enabling the use of animal models to explore this 
phenomenon, as well as raising the possibility of there being 
cross-kingdom cell–cell communication via unpasteurized milk. 
Studies in mice have identified that the absence of EVs decreases 
the diversity of the pup intestinal microbiome (130). Human stud-
ies of the role of exosomes and their cargo in modulating infant 
intestinal microbiome are limited. However, Kosaka et al. identi-
fied miRNA associated with immune regulation within exosomes 
in breast milk that are particularly abundant in the first 6 months 
of life, when the neonatal mucosal immune system is developing 
(118). Recent work investigating the role of miRNA in EVs in the 
ProPACT trial demonstrated an array of miRNA in human milk 
that differed between mothers given probiotics and those given 
placebo but no significant differences in atopy outcomes (131).
The few studies of exosomes in breast milk to date have often 
been cross-sectional (116), and there is only one study of exosomes 
in human colostrum (113); milk that is delivered at a key stage 
for early immune priming. A study of bovine exosomes shows 
that the immunomodulatory protein cargo changes temporally 
during lactation (122); thus, detailed exploration of human breast 
milk EV cargo across the course of lactation could yield data that 
are highly relevant to the development of the neonatal immune 
system. Isolation of exosomes from breast milk to investigate 
the miRNA and protein cargo that could be delivered to the 
infant mucosa would offer novel insight into potential delivery 
mechanisms for drugs with intestinal immunomodulatory fac-
tors (132). Furthermore, improved knowledge of the stability and 
functionality of EV cargoes in vivo is vital for our understanding 
of how breast milk improves neonatal health and immunity.
FUTURe DiReCTiONS
Breast Milk Microbiota
Many unanswered questions regarding the microbiome need 
further exploration. We need more studies to define the 
mechanism by which the microbiota impact immune develop-
ment and how dysbiosis leads to gut inflammation. Greater 
comprehension beyond the community profile to elucidate 
function and metabolites produced by the microbes is integral 
to utilizing these pathways to improve health or alter disease 
outcomes. If an enteromammary pathway is confirmed, we 
could exert a positive influence on infant health by modulating 
the maternal gut microbiota. Breast milk studies to date have 
mainly focused on the bacterial component. We also need to 
further understand how the milk virome and mycobiome influ-
ence infant gut health.
Breast Milk HMOs
Further questions surround the HMOs, namely, functions of 
individual HMO and synthesis of HMO in the laboratory for 
nutrition supplementation; manipulation of HMO expression; 
and their delivery to establish a healthy microbiome. It is also 
possible that early intervention (within the first few days of life) 
is required for such therapies to be successful.
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Breast Milk evs
For future studies of breast milk EVs, including exosomes, it is 
key to ensure that the correct nomenclature is utilized, based 
on the isolation methods used. Utilizing the guidelines of the 
International Society for Extracellular Vesicles (114) and report-
ing isolation methods through the new EV-TRACK database 
(133) will greatly aid the field of breast milk EVs. Apoptotic bod-
ies have been seen as something to deplete in breast milk studies 
to date. Nothing is known about their cargo nor their function 
in breast milk, but they could play an important biological func-
tion in the neonate, as seen in other fields. We also lack detailed 
understanding of how breast milk EVs change over the course of 
lactation in humans. We need to understand better how breast 
milk EVs survive in vivo in the oropharynx, nasopharynx, and 
the gut, where their delivery would be critical. Finally, a human 
model of EV interaction with the neonatal microbiome would 
also give critical insight into possible mechanisms that could 
be harnessed to protect infants from disease and aid intestinal 
immune development in term and preterm infants alike.
Summary
Future research studies should aim for enrollment of mother–
infant pairs, large sample sizes, and longitudinal sample collections 
and include a diverse population to further elucidate variability 
in the breast milk microbiome, HMOs, and EVs on infant health 
outcomes. Studies should employ metagenomics, metatranscrip-
tomics, and metabolomics approaches to understand the complete 
taxonomical, functional, and metabolic profile and create a more 
accurate picture of the breast milk contribution to infant health. 
Studies of the breast milk virome and fungome are warranted. 
Furthermore, ensuring that a repository of maternal and infant 
samples is kept for future research is useful in determining the long-
term health implications of the gut microbiome present during the 
critical window. A repository can also present the opportunity to 
study the multigenerational transmission of microbes, HMOs, and 
EVs, facilitating a comprehensive understanding of the dynamics 
of the mother’s contribution to the infant immune system.
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